-
BeiGene and GenFleet Join Forces for DLBCL Trial Combining Brukinsa and GFH009
•
BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a China-based biotechnology company, has entered into a clinical research and drug supply cooperation agreement with fellow Chinese firm GenFleet Therapeutics. The partnership will kick off a Phase Ib/II clinical trial to evaluate the safety and efficacy of a combination regimen featuring…
-
RemeGen Reports 40% Revenue Growth in 2023, but Net Losses Widen Amid Pipeline Investments
•
RemeGen Co., Ltd (HKG: 9995; SHA: 688331), a China-based biotech firm, has unveiled its 2023 financial results, reporting revenues of RMB 1.083 billion (USD 150 million), reflecting a 40.26% year-on-year increase. This growth was primarily driven by its core products: the fusion protein drug telitacicept and the HER2-targeted antibody drug…
-
Takeda Gains MHLW Approval for Adzynma, Targeting Rare Blood Disorder cTTP
•
Takeda Pharmaceutical Company (TYO: 4502) has secured regulatory approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for its enzyme replacement therapy, Adzynma (apadamtase alfa), to treat congenital thrombotic thrombocytopenic purpura (cTTP) in patients aged 12 and older. cTTP is a rare and potentially life-threatening blood clotting disorder resulting…
-
Everest Medicines Reports 884% Revenue Surge Amid Rising Losses and Strategic Shifts
•
Everest Medicines (HKG: 1952), a China-based biotech company, has released its 2023 annual financial results alongside a corporate update, revealing a staggering 884% year-on-year revenue increase to RMB 125.9 million (USD 17.4 million). However, net losses widened by RMB 597.2 million, reaching RMB 844.5 million. Notably, research and development (R&D)…
-
AstraZeneca’s Soriot Discusses US BioSecure Act’s Impact Amid China Expansion Plans
•
Pascal Soriot, CEO of AstraZeneca (NASDAQ: AZN), addressed the potential implications of the US BioSecure Act in an interview with Bloomberg during the Boao Forum for Asia in China this week. Soriot expressed that, should the act pass, “It will not necessarily affect us,” citing the “very segmented” nature of…
-
Shanghai Medicilon Forms Strategic Partnerships with Binhui Biopharmaceutical and Innoforce Pharmaceuticals
•
Shanghai Medicilon Biomedical Co., Ltd (SHA: 688202), a prominent Chinese biotech firm, has entered into separate partnerships with domestic companies Binhui Biopharmaceutical and Innoforce Pharmaceuticals Co., Ltd. In collaboration with Binhui, Medicilon aims to explore innovative areas including oncolytic viruses, nucleic acid drugs, and protein therapeutics. Meanwhile, the partnership with…
-
HutchMed’s Orpathys Files for Expanded Indication in NSCLC Treatment in China
•
HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that the National Medical Products Administration (NMPA) in China is currently reviewing a new market approval filing for Orpathys (savolitinib), a MET inhibitor co-developed with AstraZeneca. The company is seeking a new indication for the drug as a first-line treatment for…
-
Astellas Pharma’s Padcev Combo Therapy Accepted for Review in China for Urothelial Carcinoma
•
Astellas Pharma Inc. (TYO: 4503), a leading Japanese pharmaceutical company, has announced that China’s Center for Drug Evaluation (CDE) has accepted for review a supplementary Biologic License Application (sBLA) for its drug Padcev (enfortumab vedotin). The application seeks to expand the use of Padcev in combination with pembrolizumab for the…
